Search clinical trials for: TNX-102 SL 5.6 mg

Total 1457 results

Tonix Pharmaceuticals, Inc.

Completed

A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD (P306)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PREVAIL)

COVID-19 | Long COVID | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection | Long Haul COVID

United States
Tonix Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions (AtEase)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia (RESILIENT)

Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Completed

Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults

Healthy Adults

Canada
Tonix Pharmaceuticals, Inc.

Completed

Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults

Healthy Adults

Canada
Tonix Pharmaceuticals, Inc.

Terminated

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD (RECOVERY)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Completed

Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers

Healthy
Tonix Pharmaceuticals, Inc.

Terminated

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia (RE-AFFIRM)

Nervous System Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Muscular Diseases | Neuromuscular Diseases | Fibromyalgia | Myofascial Pain Syndromes

United States
Tonix Pharmaceuticals, Inc.

Completed

Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults

Healthy Adults

Canada
Tonix Pharmaceuticals, Inc.

Terminated

A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients

Primary Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Completed

Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules

Healthy Subjects

Canada
Tenax Therapeutics, Inc.
Medpace, Inc.

Recruiting

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF (LEVEL)

Pulmonary Hypertension

United States
OrthoTrophix, Inc

Completed

A Study Evaluating the Safety and Efficacy of a Second Course of TPX-100 in Subjects Who Previously Received TPX-100 for Patellar Osteoarthritis Involving Both Knees

Knee Osteoarthritis
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma
Tonix Pharmaceuticals, Inc.

Completed

A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (RELIEF)

Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Completed

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (RALLY)

Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Completed

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia (AFFIRM)

Nervous System Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Muscular Diseases | Neuromuscular Diseases | Fibromyalgia | Myofascial Pain Syndromes

United States
Engrail Therapeutics INC

Recruiting

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder (ENCALM)

Generalized Anxiety Disorder

United States
OrthoTrophix, Inc

Completed

A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees

Knee Osteoarthritis

United States
Tonix Pharmaceuticals, Inc.
Premier Research Group plc

Terminated

Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD (HONOR)

PTSD

United States
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States
Tonix Pharmaceuticals, Inc.

Completed

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions (P202)

PTSD

United States
Nektar Therapeutics

Completed

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

Malignant Solid Tumor

United States, Belgium
Bristol-Myers Squibb

Completed

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects (INH-189-006)

Hepatitis C

United States, Puerto Rico
Tonix Pharmaceuticals, Inc.

Completed

Dose-Proportionality and Food Effect Study of TNX-102 SL

Healthy Subjects

Canada
Tonix Pharmaceuticals, Inc.

Completed

12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients (BESTFIT-OLE)

Primary Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.
Premier Research Group plc

Terminated

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

PTSD

United States
Saol Therapeutics Inc

Active, not recruiting

Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain (COMPASS)

Osteoarthritis, Knee Pain

United States
Nektar Therapeutics

Completed

A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

United States
Idera Pharmaceuticals, Inc.

Completed

Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401

Waldenstrom's Macroglobulinemia
Saol Therapeutics Inc

Active, not recruiting

Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity (RAISE)

Spasticity

United States
Tonix Pharmaceuticals, Inc.

Withdrawn

Safety and Efficacy Study of TNX-102 SL in Participants With PTSD

PTSD

Kenya
H. Lundbeck A/S

Completed

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

Parkinson Disease

United States
Engrail Therapeutics INC

Withdrawn

ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures (ENACT)

Focal Epilepsy

United States
Tonix Pharmaceuticals, Inc.

Completed

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) (BESTFIT)

Primary Fibromyalgia

United States
Ente Ospedaliero Ospedali Galliera

Active, not recruiting

Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)

Iron Overload | Neurodegenerative Disease

Italy
OrthoTrophix, Inc

Completed

A Prospective Observational Study to Evaluate Long-term Changes in Cartilage Morphology in Subjects Who Previously Received TPX-100 or Placebo in Study TPX-100-1 for Patellar Osteoarthritis Involving Both Knees

Mild to Moderate Knee OA

United States
Tranzyme, Inc.

Terminated

Diabetic Gastroparesis Efficacy/Safety Study of TZP-102 (DIGEST)

Diabetic Gastroparesis

United States, Poland
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris

Acne Vulgaris

Japan
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib

Healthy

China
Nymox Corporation

Completed

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Prostate Cancer

United States
Peptigroupe Inc.

Completed

COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg

Dysfunctional Uterine Bleeding

Ukraine
Minerva Neurosciences

Completed

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Finland, Georgia, Moldova, Republic of, Poland, Ukraine
Luye Pharma Group Ltd.

Completed

Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Prostate Cancer

China
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)

Healthy Volunteer

Japan
Levo Therapeutics, Inc.

Completed

Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome (CARE-PWS)

Prader-Willi Syndrome

United States, Canada, Australia
AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
Bristol-Myers Squibb

Completed

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects (INX-189-004)

Healthy

United States

3

Subscribe